載入中
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
前收盤價
US$1.59
+US$0.05 · +3.25%
盤後
US$1.57
−US$0.02 · -1.26%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
日內區間
目前US$1.59
52週區間
目前US$1.59
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 25萬 USD | — | — |
| 毛利 | — | — | 25萬 USD | — | — |
| 研究與開發 | 1019.2萬 USD | 906.3萬 USD | 689.3萬 USD | 654.7萬 USD | 243萬 USD |
| 銷售、一般及管理費用 | 786.4萬 USD | 579.6萬 USD | 620.2萬 USD | 876.4萬 USD | 930.7萬 USD |
| 營業費用 | 1805.6萬 USD | 1485.9萬 USD | 1332萬 USD | 1572.1萬 USD | 4185.4萬 USD |
| 利息收入 | — | — | — | 1.3萬 USD | — |
| 利息支出 | 1萬 USD | 1.2萬 USD | 1.5萬 USD | 1.3萬 USD | 239.8萬 USD |
| 折舊和攤銷 | 3000 USD | 3000 USD | 4000 USD | 3000 USD | 2000 USD |
| 營業利益 | −1805.6萬 USD | −1485.9萬 USD | −1307萬 USD | −1572.1萬 USD | −4185.4萬 USD |
| 淨利 | −1678.1萬 USD | −1443.8萬 USD | −1230萬 USD | −1426萬 USD | −2661.6萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$4.50
上漲空間 183.02%評級樣本有限，僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2024年4月8日 | 1:15 | — | — |
股票分割 | 2022年11月16日 | 1:50 | — | — |
股票分割 | 2021年4月28日 | 1:6 | — | — |
股票分割 | 2019年7月18日 | 1:20 | — | — |
股票分割 | 2017年1月9日 | 1:13 | — | — |
已生效 2024年4月8日
1:15
已生效 2022年11月16日
1:50
已生效 2021年4月28日
1:6
已生效 2019年7月18日
1:20
已生效 2017年1月9日
1:13
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM625.58萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF339.66萬0.00%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO164.97萬0.01%180億 USD0.06%US$112.27-0.35%
iShares Micro-Cap ETFIWC74.75萬0.06%13.17億 USD0.60%US$181.66-0.73%
Simplify Propel Opportunities ETFSURI69.06萬0.92%7606.44萬 USD2.82%US$17.2565+0.23%
iShares Core S&P Total U.S. Stock Market ETFITOT59.19萬0.00%980.88億 USD0.03%US$169.43-0.14%
iShares Russell 2000 Growth ETFIWO37.8萬0.00%139.17億 USD0.24%US$353.71-0.86%
Avantis U.S. Small Cap Equity ETFAVSC29.5萬0.01%30.82億 USD0.25%US$69.97-0.01%iShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCSimplify Propel Opportunities ETFSURIiShares Core S&P Total U.S. Stock Market ETFITOTiShares Russell 2000 Growth ETFIWOAvantis U.S. Small Cap Equity ETFAVSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
